AtriCure Reports Third Quarter 2007 Financi...( High...),Health

Highlights

-- Total revenues of $12.1 million - up 29% over third quarter 2006

-- Net loss narrows to $2.6 million - record performance -- Domestic open-heart revenues of $6.7 million - up 22% over third quarter

2006 -- Domestic minimally invasive product revenues of $3.5 million - up 28%

over third quarter 2006

-- Record international revenues of $1.8 million - up 65% over third

quarter of 2006

-- Initial human implants - left atrial appendage clip system

-- Minimally invasive Isolator Synergy(TM) system released

WEST CHESTER, Ohio, Nov. 6 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and leader in cardiac surgical ablation systems, today announced revenues of $12.1 million for its third quarter ended September 30, 2007. The net loss for the quarter was $2.6 million, the most favorable performance since becoming a public company.

"We are encouraged by our momentum, operating leverage and overall financial performance during the third quarter. The men and women of AtriCure have amassed greater penetration and stronger market presence in each of our current business sectors. Additionally, we believe that our left atrial appendage clip system will develop into a new business sector and represents a new high growth opportunity for our Company," said David J. Drachman, President and Chief Executive Officer. "We strongly believe that no other atrial fibrillation company is better prepared or positioned than AtriCure to deliver results for patients, physicians and shareholders."

Third Quarter 2007 Fi
'/>"/>